American Heart Journal
Volume 141, Issue 2, Supplement , Pages S49-S57 , February 2001

Established and emerging cardiovascular risk factors

  • David Wood, MS, FRCP, FRCPE, FPHM, FESC
    • ,
  • on behalf of the Joint European Societies Task Force*

References 

  1. Wood D, De Backer G, Faergeman O, et al. , on behalf of the Task Force members   Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of the European and other Societies on Coronary Prevention. Eur Heart J. 1998;19:1434–1503J Hypertens. 1998;16:1407–1414Atherosclerosis. 1998;140:199–270
  2. Prevention of coronary heart disease. Report of a WHO Expert Committee. WHO Technical Report Series 678. Geneva: : World Health Organization; 1982;
  3. Barker DJP. Fetal origins of coronary heart disease. BMJ. 1995;311:171–174
  4. Cardiovascular disease risk factors: new areas for research. Report of a WHO Scientific Group. WHO Technical Report Series 841. Geneva: : World Health Organization; 1994;
  5. Anderson KM, Wilson PWF, Odell PM, et al.  An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83:356–362
  6. Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501–505
  7. Meade TW, Mellows S, Brozovic M, et al.  Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;ii:533–537
  8. Kannel WB, Wolf PA, Castelli WP, et al.  Fibrinogen and risk of cardiovascular disease. JAMA. 1987;258:1183–1186
  9. Yarnell JWG, Baker IA, Sweetman PM, et al.  Fibrinogen, viscosity, and white blood cell count are major risk factors for ischaemic heart diseases: the Caerphilly and Speewell collaborative heart disease studies. Circulation. 1991;83:836–844
  10. Bara L, Nicaud V, Tiret L, et al.  Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIc and PAI-1 in European offspring: the EARS study. Thromb Haemost. 1994;71:434–440
  11. Behague I, Poirier O, Nicaud V, et al.  Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study. Circulation. 1996;93:440–449
  12. Meade TW. Fibrinogen and other clotting factors in cardiovascular disease. In:  Francis RB editors. Atherosclerotic vascular disease, hemostasis, and endothelial function. New York: : Marcel Dekker; 1992;p. 1–32
  13. Junker R, Heinrich J, Schulte H, et al.  Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol. 1997;17:1539–1544
  14. Folsom AR, Wu KK, Shahar E, et al.  Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb. 1993;13:1829–1836
  15. Hamsten A, Wiman B, De Faire U, et al.  Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557–1563
  16. Hamsten A, de Faire U, Walldius G, et al.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;ii:3–9
  17. Eriksson P, Kallin B, Van’t Hooft FM, et al.  Allele specific increase in basal transcription of the PAI-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92:1851–1855
  18. Ye S, Green FR, Scarabin PY, et al.  The 4G/5G genetic polymorphism in the promotor of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM. Thromb Haemost. 1995;74:837–841
  19. Thaulow E, Erikssen J, Sandvik K-L, et al.  Blood platelet count and function are related to total and cardiovascular health in apparently healthy men. Circulation. 1991;84:613–617
  20. Elwood PC, Renaud S, Sharp DS, et al.  Ischaemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation. 1991;83:38–44
  21. Wu KK. Genetic markers: genes involved in thrombosis. J Cardiovasc Res. 1997;4:347–352
  22. Weiss EJ, Bray PF, Tayback M, et al.  A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090–1094
  23. Walter DH, Schachinger V, Elsner M, et al.  Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 1997;350:1217–1219
  24. Boushey C, Beresford SAA, Omenn G, et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057
  25. Alfthan G, Pekkanen J, Jauhianen M, et al.  Relations of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9–19
  26. Evans RW, Shaten BJ, Hempel JD, et al.  Homocysteine and risk of cardiovascular disease in Multiple Risk Factor Interventional Trial. Arterioscler Thromb Vasc Biol. 1997;17:1947–1953
  27. Graham IM, Daly LE, Refsum HM, et al.  Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775–1781
  28. Harmon DL, Woodside JV, Yarnell JWG, et al.  The common “thermolabile” variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q J Med. 1996;89:571–577
  29. Jacques PF, Bostom AG, Williams RR, et al.  Relation between folate status, a common mutation in methylene-tetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7–9
  30. Haverkate F, Thompson SG, Pyke SD, et al.  Pruduction of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:461–466
  31. Kuller LH, Tracey RP, Shaten J, et al.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144:537–547
  32. Ridker PM, Cushman M, Stampfer MJ, et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  33. Ridker PM, Glynn RJ, Hennekens CH. C-reacive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011
  34. Koenig W, Frohlich M, Sund M, et al.  C-reactive protein (CRP) predicts the risk of coronary heart disease (CHD) in healthy middle-aged men: results from the MONICA-Augsburg cohort study, 1984/85-1992 [abstract]. Circulation. 1997;96(suppl I):I-99
  35. Tracy R, Lomalue R, Psaty B, et al.  Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121–1127
  36. Ridker PM, Cushman M, Stampfer MJ, et al.  Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425–428
  37. Mendall MA, Patel P, Asante M, et al.  Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 1997;78:273–277
  38. Danesh J, Collins R, Appleby P, et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477–1482
  39. Ridker PM, Hennekens CH, Roitman-Johnson B, et al.  Plasma concentrations of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88–92
  40. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link?. Lancet. 1997;350:430–436
  41. Muhlestein JB, Hammond EH, Carlquist JF, et al.  Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996;27:1555–1561
  42. Gupta S, Leatham EW, Carrington D, et al.  Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404–407
  43. Gurfinkel E, Bozovich G, Daroca A, et al. , for the ROXIS Study Group   Randomised trial of roxithromycin in non Q wave coronary syndromes: ROXIS pilot study. Lancet. 1997;350:404–407
  44. Wilson PWF, Schaefer EJ, Larson MG, et al.  Apolipoprotein E allele and risk of coronary disease a meta-analysis. Arterioscler Thromb Vasc Biol. 1996;16:1250–1255
  45. Cambien F, Evans AE. The angiotensin-I converting enzyme (ACE) gene polymorphism and coronary heart disease. Eur Heart J. 1995;16(suppl K):K13–K22
  46. Montgomery HE, Clarkson P, Dollery CM, et al.  Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation. 1997;96:741–747
  47. Amant C, Bauters C, Bodart JC, et al.  D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation. 1997;96:56–60
  48. Ribichini F, Steffenino G, Dallavalle A, et al.  Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme is a major risk factor and a marker of risk of coronary stent restenosis. Circulation. 1998;97:147–154
  49. Pinto YM, van Gilst WH, Kingma H, et al.  Deletion-allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. J Am Coll Cardiol. 1995;25:1622–1626
  50. Andersson B, Sylven C. The DD genotype of the angiotensin converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol. 1996;28:162–167
  51. Montgomery HE, Clarkson P, Nwose OM, et al.  The acute rise in plasma fibrinogen concentration with exercise is influenced by the G453A polymorphism of the fibrinogen gene. Arterioscler Thromb Vasc Biol. 1996;16:386–391
  52. Gardemann A, Schwartz O, Haberbosh W, et al.  Positive association of the fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost. 1997;77:1120–1126
  53. De Maat MPM, Kastelein JJP, Jukema JW, et al.  455G/A polymorphism of the fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men. Arterioscler Thromb Basc Biol. 1998;18:265–271
  54. Fumeron F, Betoulle D, Luc G, et al.  Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest. 1995;96:1664–1671
  55. Cusi D, Barlassina C, Azzani T, et al.  Polymorphisms of a-adducin and salt sensitivity in patients with essential hypertension. Lancet. 1997;349:1353–1357
  56. Bowker TJ, Clayton TC, Ingham J, et al.  A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE. Heart. 1996;75:334–342
  57. EUROASPIRE study group . A European Society of Cardiology survey of secondary prevention of CHD: principal results. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J. 1997;18:1569–1592

☆ *Members of the Task Force are listed in the Appendix.

☆☆ This paper is based on the Joint European Societies Task Force recommendations on prevention of coronary heart disease in clinical practice, published in the European Heart Journal 1998;19:1434-503.

★ Reprint requests: Professor David Wood, Cardiac Medicine/Clinical Epidemiology Unit, National Heart and Lung Institute, Dovehouse St, London SW3 6LY, United Kingdom.

PII: S0002-8703(01)70044-0

American Heart Journal
Volume 141, Issue 2, Supplement , Pages S49-S57 , February 2001

Article Tools

* Image Usage & Resolution